ZKSCAN2 Inhibitors
Chemical inhibitors of ZKSCAN2 can affect its function primarily through the disruption of signaling pathways and modification of chromatin structure, which are vital for its role in transcriptional regulation. MEK inhibitors such as PD98059 and U0126 can inhibit the MEK-ERK pathway, crucial for the regulation of transcription factors that ZKSCAN2 may interact with or depend upon. Similarly, the PI3K inhibitors LY294002 and Wortmannin can decrease the activation of the Akt pathway, leading to a reduction in transcription factor activity and thus inhibiting the function of ZKSCAN2. The JNK inhibitor SP600125 obstructs the JNK signaling, which is also implicated in the modulation of transcription factors and chromatin remodeling, all of which are important for the function of ZKSCAN2. SB203580 targets the p38 MAP kinase, another key player in stress response signaling and transcription factor regulation, whose inhibition could disrupt ZKSCAN2's transcriptional regulation capabilities.
In addition to signaling inhibitors, compounds that directly alter the chromatin state also play a role in inhibiting ZKSCAN2. Trichostatin A and Apicidin, both HDAC inhibitors, can lead to hyperacetylation of histones, thus affecting the chromatin structure and potentially inhibiting the engagement of ZKSCAN2 with its transcriptional targets. 5-Azacytidine acts by inhibiting DNA methyltransferase, leading to hypomethylation of DNA, which can alter transcription factor binding sites and may adversely affect ZKSCAN2's ability to regulate gene expression. Rapamycin, an mTOR inhibitor, can alter transcriptional processes by affecting growth signal pathways, which has downstream effects on ZKSCAN2's regulatory functions. Staurosporine's broad-spectrum kinase inhibition can lead to reduced phosphorylation of proteins involved in transcriptional regulation, thus indirectly inhibiting ZKSCAN2. Lastly, KN-93's inhibition of CaMKII may impair the activation of transcription factors that are necessary for ZKSCAN2's function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As a MEK inhibitor, PD98059 can inhibit the MEK-ERK pathway, which is crucial for transcription factor regulation and may be necessary for ZKSCAN2 function. Inhibition of this pathway leads to a reduction in ZKSCAN2 activity as it relies on specific transcriptional events for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which is upstream of the Akt signaling pathway. Since the Akt pathway can regulate DNA binding of transcription factors, LY294002 inhibition of PI3K would decrease Akt activation, thereby inhibiting ZKSCAN2's function within transcriptional regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that can prevent the activation of ERK, a kinase involved in the transcription factor activity that ZKSCAN2 could be part of. By inhibiting this pathway, U0126 reduces ZKSCAN2's transcriptional regulatory function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can be involved in transcription factor modulation and chromatin remodeling. By inhibiting JNK, SP600125 can disrupt transcriptional processes and chromatin states that ZKSCAN2 may utilize to exert its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP kinase, which is involved in stress response and modulation of transcription factors. Inhibition of p38 MAP kinase can lead to the functional inhibition of ZKSCAN2 by disrupting the transcriptional regulation pathways it operates within. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor like LY294002, and it inhibits the Akt pathway. Inhibition of PI3K by Wortmannin would lead to decreased Akt activity, thus inhibiting the potential regulation of transcription factors and chromatin remodeling by ZKSCAN2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can affect transcriptional processes and chromatin structure by influencing cell growth signals. By inhibiting mTOR, Rapamycin may reduce the transcriptional regulatory activity of ZKSCAN2. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylase (HDAC), which can affect chromatin structure and gene expression. As ZKSCAN2 is involved in transcriptional regulation, inhibition of HDAC can result in altered chromatin states, thereby inhibiting ZKSCAN2's ability to regulate transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine inhibits DNA methyltransferase, leading to a reduction in DNA methylation. Since DNA methylation can influence transcription factor binding, this inhibition can disrupt the transcriptional regulatory function of ZKSCAN2 by altering its DNA interaction. | ||||||
Apicidin | 183506-66-3 | sc-202061 sc-202061A | 1 mg 5 mg | $110.00 $343.00 | 9 | |
Apicidin, as an HDAC inhibitor, changes the acetylation status of histones, which impacts chromatin structure and gene expression. Inhibition of HDAC by Apicidin can affect the transcriptional regulatory function of ZKSCAN2. | ||||||